Quantitative PET Imaging with Novel HER3-Targeted Peptides Selected by Phage Display to Predict Androgen-Independent Prostate Cancer Progression

Abstract

Funding from this award has permitted the development of a highly specific peptide that targets HER3 for prostate cancer imaging. The peptide was labeled with a PET imaging radionuclide and injected into mice bearing human prostate cancer. The peptide accumulated at high levels in the tumors, and excisional analysis revealed quantitative accumulation of the peptide in tumors that was linearly correlated with HER3 levels. Biodistribution analysis revealed low off-target accumulation and rapid clearance through the renal system, consistent with small peptides. The peptide represents a promising clinical lead for HER3 imaging in patients with castration resistant prostate cancer.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Dec 01, 2017
Accession Number
AD1048753

Entities

People

  • Benjamin Larimer

Organizations

  • Massachusetts General Hospital

Tags

DTIC Thesaurus Topics

  • Androgen Receptors
  • Androgens
  • Biomedical Research
  • Breast Cancer
  • Castration
  • Cells
  • Chemistry
  • Digital Data
  • Digital Information
  • Health Services
  • Hospitals
  • Maryland
  • Massachusetts
  • Metadata
  • Neoplasms
  • Nuclear Medicine
  • Patent Applications
  • Photographic Film
  • Photographic Materials
  • Photographic Recording Media
  • Photography
  • Prostate
  • Prostate Cancer
  • Proteins
  • Specialty Uses Of Chemicals
  • Transparencies

Fields of Study

  • Physics

Readers

  • Oncology (Cancer Research).